WA
PTGX icon

WPG Advisers’s Protagonist Therapeutics PTGX Stock Holding History

WPG Advisers’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Buy
107
+10
+10% +$1.04K 0.01% 686
2026
Q1 		$10.2K Buy
97
+1
+1% +$89 0.01% 665
2025
Q4 		$8.38K Buy
96
+18
+23% +$1.47K 0.01% 757
2025
Q3 		$5.18K Hold
78
– – ﹤0.01% 896
2025
Q2 		$4.31K Buy
78
+70
+875% +$3.36K ﹤0.01% 927
2025
Q1 		$387 Buy
+8
New +$335 ﹤0.01% 1375

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

WPG Advisers's PTGX Position: Q2 2026 in Review

WPG Advisers increased its Protagonist Therapeutics (PTGX) stake by 10% in Q2 2026, buying an estimated $1.04K and bringing the position to 107 shares worth $13.1K. The position accounts for 0.01% of the portfolio, ranked #686.

WPG Advisers first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. 134 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • WPG Advisers held 107 shares of Protagonist Therapeutics worth $13.1K as of Q2 2026.
  • WPG Advisers bought 10 Protagonist Therapeutics shares in Q2 2026, an estimated $1.04K.
  • Protagonist Therapeutics made up 0.01% of WPG Advisers's portfolio in Q2 2026, its #686 holding.
  • WPG Advisers first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 134 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.